Skip to main content

Table 4 Hazard ratiosa according to tertiles of serum 25(OH)D and chemotherapy

From: Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study

 

Serum 25(OH)D

 

Continuous

Categorized

 

per 10 nmol/L decrement

< 35 nmol/L

35-55 nmol/L

≥ 55 nmol/L

Outcome

No.

(events)

HR

95% CI

P trend b

No.

(events)

HR

95% CI

No.

(events)

HR

95% CI

No.

(events)

HR

95% CI

Overall mortality

             

   All

1,265 (174)

1.08

1.00 to 1.17

0.07

422 (82)

1.55

1.00 to 2.39

397 (44)

0.72

0.45 to 1.17

446 (48)

1.00

-

   No/before CTc

911 (99)

1.15

1.03 to 1.27

0.02

292 (51)

2.17

1.18 to 3.99

276 (20)

1.00

0.51 to 1.96

343 (28)

1.00

-

   After CTd

339 (71)

0.91

0.75 to 1.08

0.27

121 (29)

0.82

0.35 to 1.95

117 (22)

0.59

0.24 to 1.44

101 (20)

1.00

-

Distant disease

             

   All

1,074 (135)

1.14

1.05 to 1.24

0.006

338 (63)

2.09

1.29 to 3.41

342 (37)

1.16

0.70 to 1.94

394 (35)

1.00

-

   No/before CTc

844 (103)

1.17

1.06 to 1.29

0.005

259 (50)

2.41

1.37 to 4.22

263 (26)

1.07

0.59 to 1.94

322 (27)

1.00

-

   After CTd

221 (32)

1.12

0.85 to 1.39

0.41

73 (13)

1.79

0.35 to 9.00

78 (11)

0.84

0.14 to 4.97

70 (8)

1.00

-

  1. Note: 18 and 9 participants, respectively, had missing data on chemotherapy and were excluded from the stratified analyses.
  2. 25(OH)D, 25-hydroxyvitamin D; CI, confidence interval; CT, chemotherapy; HR, hazard ratio.
  3. a Stratified by age at diagnosis and season, adjusted for tumor size, nodal status, metastases, tumor grade, estrogen/progesterone receptor status, diabetes, mode of detection
  4. b Calculated by using serum 25(OH)D as a continuous variable.
  5. c No chemotherapy or blood collection before start chemotherapy.
  6. d Blood collection after start chemotherapy.
  7. Pinteraction = 0.06 and 0.49 for overall mortality and distant disease, respectively.